Drew Hykes: Sure, so first part of your question related to clot removal and blood loss. Thankfully, we can point to the two largest prospective registries ever conducted in venous thrombectomy to use data to answer the question, how effective ClotTriever remove clot. You can look at the CLOUT data and see very effectively the vast majority of patients we removed the vast majority of CLOUT regardless of chronicity blood loss in the CLOUT registry was 40 milliliters. So you can see very objectively in the data, the kind of performance that we have from a clot removal and blood loss perspective. See the same thing when you look at FlowTriever relative to the FLASH industry, blood loss there, for instance, you heard in the prepared remarks, 100 milliliters.
We’ve had line of sight to a couple of dozen CAT 16 cases at this point. And the average blood loss that we’re seeing, catalog in those cases is north of 500 milliliters. Certainly 1,000 milliliters is north of that even. Keep in mind, that’s a pretty significant part of the overall blood volume, 20% of the blood volume so obviously, a very significant clinical finding to have that amount of blood loss. And it’s not insignificant. Tom can talk more specifically about some of the clinical implications, but blood loss is a known risk factor for all interventional procedures and venous thrombectomy is no different.
Larry Biegelsen: Okay, thank you very much.
Drew Hykes: Thanks Larry.
Operator: The next question is from Adam Maeder with Piper Sandler. Please go ahead.
Adam Maeder: Hi, good afternoon, guys. Thank you for taking the questions. I wanted to start on guidance construction, and test my luck there. I guess as we look at the 23% to 25% year-over-year growth, is it reasonable to think that 20% plus of that growth is from the core business? And can you just elaborate a little bit how you’re thinking about ClotTriever and FlowTriever growth this year? I guess that’s the first one. And then I have a follow-up or two? Thanks.
Drew Hykes: Yes, I can start on that, Adam, and Mitch may want to chime in as well. I think the way we constructed guidance, as you heard Mitch mentioned earlier, we were very deliberate about contemplating all the different dynamics across the business, the core business, the new TAMs, U.S., OUS, competitive dynamics, pricing, all of those factors were contemplated in the guidance. It was, at the same time, I think, largely driven by or reflective of our confidence and the continued growth of the core VTE franchise here in the U.S. That’s obviously the largest part of the business still. The part of the business we have best line of sight and can forecast most confidently. So that 24% growth at the midpoint, I think, is clearly driven by and reflective of our confidence in the core franchise.
And then as you add on, the new products and the new TAMs, I think its additive to that core and then clearly, continued traction internationally is also additive to the core. Relative to the composition between ClotTriever and FlowTriever, I think just like we saw in Q4, we would anticipate continued balanced growth across the franchise. That mix and the contribution of the two on a relative basis, has been fairly consistent. Over time, we see some quarter-to-quarter fluctuations. But as we thought about guidance this year, I think, by and large, we contemplated a relatively consistent, balanced contribution from both FlowTriever and ClotTriever.
Adam Maeder: That’s really helpful, Drew. I appreciate that. And I guess just one clarification as it relates to Artix. So when you issued the guidance in January for the first time for 2023 revenue, was anything baked into that guidance range for Artix? I just wanted to clarify that. And then for the follow-up, I was hoping you could just talk a little bit more about the FLAME study that you have at ACC in the coming days? I think you’ve talked about potential to eventually change guidelines, and I think you’re hopeful that FlowTriever will see an outsized benefit there. So maybe just kind of walk through time lines there and how you think about potential impact to your business? Thanks for taking the questions.
